A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas
NCT05113069 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 170
Last updated 2023-12-06
Summary
To assess the safety and tolerability of SHR-A1912 in patients with B cell lymphoma, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1912.
Conditions
- B Cell Lymphoma
Interventions
- DRUG
-
SHR-A1912
SHR-A1912, dose escalation and expansion.
Sponsors & Collaborators
-
Shanghai Hengrui Pharmaceutical Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-22
- Primary Completion
- 2024-03-31
- Completion
- 2025-03-30
Countries
- China
Study Locations
More Related Trials
-
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
NCT01718691 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
NCT05040906 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression
NCT05189197 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
NCT05039658 ·Status: UNKNOWN ·Phase: PHASE1
-
Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma
NCT06251180 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas
NCT03218072 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics, Efficacy and Safety of the 304 Injection
NCT03980379 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
NCT05200312 ·Status: UNKNOWN ·Phase: PHASE2
-
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
NCT05926427 ·Status: RECRUITING ·Phase: PHASE2
-
Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor
NCT03664297 ·Status: UNKNOWN ·Phase: PHASE1
-
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
NCT06594432 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma
NCT03900377 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
NCT05690191 ·Status: ENROLLING_BY_INVITATION
-
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
NCT00794638 ·Status: COMPLETED ·Phase: PHASE1
-
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
NCT06033820 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
NCT05201248 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
NCT05097443 ·Status: UNKNOWN ·Phase: PHASE3
-
Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
NCT05495828 ·Status: RECRUITING
-
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
NCT00412997 ·Status: COMPLETED ·Phase: PHASE1
-
Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT
NCT05896007 ·Status: RECRUITING ·Phase: PHASE2
-
RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT03485118 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
NCT03299738 ·Status: UNKNOWN ·Phase: PHASE1
-
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT06693973 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
NCT00499018 ·Status: UNKNOWN ·Phase: PHASE3
-
The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.
NCT05428670 ·Status: UNKNOWN ·Phase: PHASE2